Funding Program between Oxurion and Negma Ends
02 March 2023 - 6:00PM
Funding Program between
Oxurion and
Negma
Ends
Leuven, BELGIUM, Boston, MA, US
– March 2, 2023
8:00 am CET – Oxurion NV (Euronext Brussels: OXUR) a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, with clinical stage assets in vascular
retinal disorders, and Negma Group, a diversified investment
company, announce today that their funding program has ended,
pursuant to the terms and conditions of the Issuance and
Subscription agreement entered into by the Company with the Negma
Group on August 26, 2021, as amended on September 2, 2022 and
January 25, 2023.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.
Important
information about
forward-looking statements
Certain statements in this press release may be considered
“forward-looking”. Such forward-looking statements are based on
current expectations, and, accordingly, entail and are influenced
by various risks and uncertainties. The Company therefore cannot
provide any assurance that such forward-looking statements will
materialize and does not assume any obligation to update or revise
any forward-looking statement, whether as a result of new
information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No securities
of Oxurion may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or
in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
For further
information please
contact:
Oxurion NV Tom GraneyChief Executive Officer Tel: +32 16 75 13
10tom.graney@oxurion.com |
USConway CommunicationsMary T.
Conwaymtconway@conwaycommsir.com |
Michael DillenChief Business Officer Tel: +32 16 75 13
10michael.dillen@oxurion.com |
ICR Westwicke Christopher Brinzey Tel: +1 617 835
9304Chris.Brinzey@westwicke.com |
- Oxurion and Negma end Funding Program.FINAL
Oxurion NV (EU:OXUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxurion NV (EU:OXUR)
Historical Stock Chart
From Apr 2023 to Apr 2024